Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Optimal Dosage of Ticagrelor in Korean Patients With AMI

East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for

  • 0 views
  • 24 Mar, 2022
  • 1 location
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus (OPTIMUS-7)

. The aim of this study is to assess the PD effects of ticagrelor 60 mg with and without aspirin therapy in CAD patients and to compare this with a standard DAPT regimen of aspirin plus clopidogrel.

  • 0 views
  • 15 Jun, 2022
  • 1 location
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) (STAR-T)

Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-ATR system for intraoperative removal of ticagrelor in patients

  • 0 views
  • 28 Jun, 2022
  • 19 locations
Efficacy of Ticagrelor Plus Aspirin in Minor Non-cardioembolic Ischemic Stroke

,Iran.The aim of study is assess the efficacy of ticagrelor plus aspirin in reduce of minor non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3 months.

  • 0 views
  • 12 Sep, 2021
  • 2 locations
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not

This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients

aspirin
ticagrelor
reperfusion therapy
enoxaparin
myocardial reperfusion
  • 0 views
  • 07 Jul, 2021
  • 1 location
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug (KF2019#1)

bioavailability of rosuvastatin by transporting rosuvastatin from enterocytes back to the gut lumen. Inhibition of BCRP can increase rosuvastatin bioavailability and systemic concentrations. Ticagrelor is a

Accepts healthy volunteers
  • 0 views
  • 26 May, 2022
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (DAPT-SHOCK-AMI)

Multicenter randomized double blind trial comparing intravenous cangrelor and oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock and treated

infarct
hypoperfusion
percutaneous coronary intervention
vasopressor
ticagrelor
  • 24 views
  • 12 Feb, 2022
  • 25 locations
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI (SWAP-AC-2)

response to clopidogrel. Although practice recommendations indicate that the use of potent P2Y12 inhibitors (i.e., ticagrelor) may be considered in patients at increased thrombotic risk, they do not

aspirin
dapt
ticagrelor
clopidogrel
  • 0 views
  • 21 Mar, 2022
  • 1 location
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy

Accepts healthy volunteers
  • 0 views
  • 10 May, 2022
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG

injury (including reflux esophagitis) after 6 and 12 months of PPI treatment combined with two different DAPT regimens (clopidogrel plus aspirin or ticagrelor plus aspirin).

  • 0 views
  • 01 Jul, 2021
  • 1 location